Welcome to our dedicated page for CMNDF news (Ticker: CMNDF), a resource for investors and traders seeking the latest updates and insights on CMNDF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CMNDF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CMNDF's position in the market.
On February 1, 2022, Clearmind Medicine Inc. (OTCMKTS: CMNDF) approved 2,020,000 stock options with an exercise price no lower than $0.56, targeting company directors and officers. Additionally, 60,000 restricted stock units (RSUs) will be issued monthly over 24 months to three consultants, who can be terminated without notice. Clearmind focuses on developing psychedelic-derived therapeutics for health problems like alcohol use disorder and holds four patent families, with plans for further intellectual property acquisition.
Clearmind Medicine Inc. (CMNDF) announced a joint venture with Medigus Ltd. to develop food supplements based on Clearmind's unique psychedelics intellectual property. The agreement includes a private placement investment of CAD$1.6 million from Medigus. Clearmind will issue 1,987,344 Units at a subscription price of CAD$0.80 per Unit, with each Unit comprising a common share and a warrant. Medigus will hold 10% equity in the psychedelics venture. Clearmind focuses on developing therapeutic solutions for untreated health issues.
Clearmind Medicine has announced that its common shares are now fully eligible for settlement through the Depository Trust Company (DTC). This development is expected to enhance the trading process for U.S. investors and increase liquidity. The company, listed under the ticker CMNDF on the OTC Markets, focuses on developing psychedelic-derived therapeutics aimed at addressing serious health issues. DTC eligibility accelerates settlement and reduces costs for investors and brokers, which could potentially lead to greater interest in Clearmind's offerings.
Clearmind Medicine Inc. (CMNDF) announced a virtual event featuring Dr. Gabor Maté on February 3, 2022. This event, part of their "Psychedelics for Alcoholism" series, aims to discuss alcohol use disorder and trauma. Dr. Maté, a renowned expert, will provide insights on these issues, aligning with Clearmind's focus on developing psychedelic-derived therapeutics. CEO Dr. Adi Zuloff-Shani highlighted the collaboration's significance in addressing mental health challenges. The event is free and open to all, with registration required.
Clearmind Medicine Inc. (CMNDF), a biotech company focused on psychedelic therapeutics, has engaged Independent Trading Group for market-making services to enhance share liquidity. Additionally, the firm has appointed Thunder11 as its PR agency to boost its profile in the U.S. market. Clearmind aims to develop novel psychedelic-derived treatments for health issues like alcohol use disorder, holding four patent families. The company is actively seeking to expand its intellectual property portfolio.
Clearmind Medicine Inc. is set to host a free online event on January 26, 2022, at 12 p.m. EST, titled Psychedelics For Alcoholism. The event will cover the regulatory journey of Clearmind's patented MEAI molecule towards FDA approval for treating alcohol use disorder and binge drinking. Key speakers include CEO Adi Zuloff-Shani and VP Mark Haden. Attendees will learn about the potential of MEAI-based therapies and the FDA approval process. Registration is free and open to all interested parties.
Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) recently announced that their new VP of Business Development, Mark Haden, presented new psychedelic substances at the Canadian Psychedelics Association event. This event was exclusive to medical professionals and focused on novel psychedelic treatments, particularly MEAI, aimed at addressing alcohol-use disorder. The company’s involvement in such exclusive discussions highlights its commitment to promoting its innovative treatments and engaging with potential partners in North America.
Clearmind Medicine Inc. has announced the appointment of Mark Haden as VP of Business Development and Gilad Babchuk as Head of Strategy and Communication. Haden, a leading expert in psychedelic medicine, has extensive research experience, including work on psilocybin for substance use disorders. Babchuk brings 28 years of experience in organizational development. CEO Dr. Adi Zuloff-Shani expressed confidence that their expertise will enhance Clearmind's growth in North America as the company focuses on developing psychedelic-derived therapeutics.
Clearmind Medicine Inc. (CMNDF) has announced a new agreement to collaborate with the Hebrew University of Jerusalem in Israel. This partnership aims to advance research on novel patentable psychedelics for potential treatment of mental health disorders. The company's focus lies in developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder. Clearmind possesses four patent families and intends to expand its intellectual property portfolio.
Clearmind Medicine Inc. has announced a partnership with the Hebrew University of Jerusalem to advance research on its proprietary compound, MEAI, targeting binge eating and obesity. The study will assess MEAI's effects on food and water intake, along with its metabolic impact. With rising obesity rates—74% of U.S. adults overweight and 40% obese—there's a critical need for effective treatments. Prof. Joseph Tam will oversee the three-phase study, which aims to demonstrate MEAI's therapeutic potential. The company's focus remains on developing psychedelic-derived therapeutics.
FAQ
What is the market cap of CMNDF (CMNDF)?
